Lophius Biosciences has reported about the successful presentation of very recent study results with T-Track® CMV and T-Track® EBV tests at a number of leading scientific congresses such as the 24th International Congress of the Transplantation Society (TTS), the 9th Annual Meeting of the Deutschen Vereinten Gesellschaft für Klinische Chemie und Laboratoriumsmedizin (DGKL), the 4th Annual Meeting of the German Society for Nephrology (DGfN) and the joint meeting of both European and American Society for Transplantation (ESOT/AST).
Lophius Biosciences will also present at the 44th Congress of the Swiss Society for Nephrology at the beginning of December 2012.
Besides a detailed presentation of the recent clinical validation study, the company also presented first results concerning the application of both CE-marked tests as standardized assay systems for the determination of the cell-mediated immune response in transplant patients.
In appreciation for the scientific quality of the presented work, Lophius Biosciences received the poster award at the meeting of the German Society for Nephrology (DGfN) in Hamburg.
"We are very pleased about the feedback and recognition we have gained for our scientific work for both T-Track® CMV and T-Track® EBV tests. This will provide a strong support for our aim to establish full clinical benefits of these novel T-cell based diagnostics in the field of transplantation and other indications with high medical need" said Dr. Michael Lutz, CEO of Lophius Biosciences.